ArticleNeurology(R) neuroimmunology & neuroinflammation2016
No association of tobacco use and disease activity in multiple sclerosis.
Open access · goldAbstract read
In one paragraph
Article in Neurology(R) neuroimmunology & neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.Neurology · 2020Trial
- Impact of tobacco and alcohol consumption on disease progression and MRI in people with multiple sclerosis: results of the prospective cohort study NationMS.Therapeutic advances in neurological disorders · 2026Article
- Relation Between Smoking and Disability Progression in Iranian Multiple Sclerosis Patients: A Case-Control Study.International journal of preventive medicine · 2025Article
- The Effect of Smoking and Passive Exposure on Multiple Sclerosis and Correlation with IL17 & IL23 Levels.Noro psikiyatri arsivi · 2025Article
- Impact of tobacco smoking on disease-specific outcomes in common neurological disorders: A scoping review.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2024Article
- The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Associations of Alcohol Consumption and Smoking With Disease Risk and Neurodegeneration in Individuals With Multiple Sclerosis in the United Kingdom.JAMA network open · 2022Article
- Associations between smoking and walking, fatigue, depression, and health-related quality of life in persons with multiple sclerosis.Acta neurologica Belgica · 2021Article
- The health burden of non-communicable neurological disorders in the USA between 1990 and 2017.Brain communications · 2020Article
- Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Silje KvistadDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Kjell-Morten MyhrDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Trygve HolmøyDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Jūratė Šaltytė BenthDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Kristin I Løken-AmsrudDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Stig WergelandDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Antonie G BeiskeDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Kristian S BjerveDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Harald HovdalDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Finn LilleåsDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Rune MidgardDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Tom PedersenDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Søren J BakkeDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Øivind TorkildsenDepartment of Immunology and Transfusion Medicine (S.K.), Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (S.K., S.W., Ø.T.), and Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology (K.-M.M., S.W., Ø.T.), Haukeland University Hospital, Bergen; KG Jebsen MS Research Centre (S.K., K.-M.M., Ø.T.), Department of Clinical Medicine, University of Bergen; Department of Neurology (T.H.), and HØKH, Research Centre (J.Š.B.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H., J.Š.B.), University of Oslo; Department of Neurology (K.I.L.-A.), Innlandet Hospital Trust, Lillehammer; Multiple Sclerosis Centre Hakadal (A.G.B.); Clinic of Laboratory Medicine (K.S.B.) and Department of Neurology (H.H.), St. Olavs Hospital, Trondheim University Hospital; Department of Laboratory Medicine (K.S.B.), Children's and Women's Health, Norwegian University of Science and Technology, Trondheim; Curato Oslo (F.L.); Department of Neurology (R.M.), Molde Hospital; Unit for Applied Clinical Research (R.M.), Norwegian University of Science and Technology, Trondheim; Unilabs Drammen (T.P.), Drammen; and Department of Neuroradiology (S.J.B.), Oslo University Hospital Rikshospitalet, Norway.
Norwegian Womens Public Health Association · NO
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study whether tobacco use is associated with MRI and clinical disease activity in patients with multiple sclerosis (MS).
methodsProspective cohort study of 87 patients with relapsing-remitting MS originally included in a randomized placebo-controlled trial of omega-3 fatty acids in MS (the OFAMS Study). Serum levels of cotinine (biomarker of tobacco use) were analyzed at baseline and every 6 months for 2 years. MRI activity was assessed at baseline and monthly for 9 months and after 12 and 24 months.
resultsFifty-three patients (61%) had serum cotinine levels ≥85 nmol/L on ≥60% of the measurements and were considered tobacco users and 34 (39%) had cotinine levels <85 nmol/L, consistent with non-tobacco use. There was no association between tobacco use and the occurrence of new gadolinium-enhancing T1 lesions, new or enlarging T2 lesions, or their aggregate (combined unique activity). Furthermore, there was no association between cotinine levels and MRI activity for the tobacco users, and tobacco users did not have more relapses or Expanded Disability Status Scale progression.
conclusionOur results indicate that tobacco use does not directly influence MRI activity or relapse rate in MS. This may implicate that the reported association between smoking and MS disease progression could be mediated through other mechanisms.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.